Saranac Partners Ltd Acquires Shares of 150,265 Boston Scientific Corporation $BSX

Saranac Partners Ltd acquired a new position in Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 150,265 shares of the medical equipment provider’s stock, valued at approximately $6,424,000. Boston Scientific makes up about 1.9% of Saranac Partners Ltd’s investment portfolio, making the stock its 24th biggest position.

Several other large investors also recently made changes to their positions in BSX. FWL Investment Management LLC acquired a new position in Boston Scientific during the 2nd quarter worth about $26,000. Swiss RE Ltd. acquired a new stake in Boston Scientific in the 4th quarter valued at about $26,000. Garton & Associates Financial Advisors LLC bought a new position in shares of Boston Scientific in the fourth quarter worth about $26,000. Sfam LLC acquired a new position in shares of Boston Scientific during the fourth quarter worth approximately $29,000. Finally, Cresta Advisors Ltd. bought a new stake in shares of Boston Scientific during the fourth quarter valued at approximately $33,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Up 0.0%

Boston Scientific stock opened at $50.39 on Monday. Boston Scientific Corporation has a fifty-two week low of $42.20 and a fifty-two week high of $109.50. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The firm has a market capitalization of $73.03 billion, a price-to-earnings ratio of 20.40, a PEG ratio of 1.10 and a beta of 0.56. The company’s 50 day simple moving average is $46.34 and its 200 day simple moving average is $57.62.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same period last year, the business posted $0.75 earnings per share. The business’s revenue for the quarter was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, sell-side analysts anticipate that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific declared that its board has authorized a stock buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling

In other Boston Scientific news, CEO Michael F. Mahoney purchased 186,240 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were bought at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the transaction, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. This trade represents a 13.27% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David C. Habiger acquired 2,100 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were acquired at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the acquisition, the director directly owned 17,160 shares in the company, valued at $816,644.40. This represents a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have acquired 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms recently weighed in on BSX. Raymond James Financial restated an “outperform” rating and issued a $57.00 price objective on shares of Boston Scientific in a research report on Thursday, July 30th. Zacks Research downgraded shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a research report on Friday, June 5th. Stifel Nicolaus set a $60.00 target price on shares of Boston Scientific in a research note on Wednesday, July 29th. Weiss Ratings lowered shares of Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, July 7th. Finally, BTIG Research cut their price target on Boston Scientific from $65.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, July 29th. Twenty-four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $71.62.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.